This has been analysed in hepatocellular carcinoma, colorectal carcinoma and lung cancer whereby treatment to respective cell lines of HepG2 by Sorafenib [80], HCT116 by Indomethacin [85] and A549 cells by Eurycomanone [86] resulted in significant down-regulation of ANXA1 protein expression. This evidence concerns the gene ANXA1 and hepatocellular carcinoma.